Abrégé

Provided are systems and methods for performing germfree or concurrent germfree and gnotobiotic animal studies in the same room. The system can include one or more isolation individually ventilated cages equipped with HEPA-filtered positive-pressurization housing at least one animal that is germfree, a fecal transplantee, or gnotobiotic. An air handling unit provides filtered air to each of the IsoIVC-Ps when stored on a support rack. Each of the IsoIVCPs can be self-hermetically sealed when removed from the support rack. The system can also include one or more isolators, where each isolator is an aseptic glovebox isolator comprising a hydrogen peroxide vapor module. Concurrent animal studies can be performed by sterilizing, via autoclave, the IsoIVC-Ps, which are then inserted into the isolator. The animal-occupied IsoIVCPs are hermetically sealed while in the isolator and sterilized by hydrogen peroxide vapor. Then the animal-occupied IsoIVC-Ps can be opened inside the isolator for study.

Classes IPC  ?

• B01L 1/02 - Chambres pressuriséesLeurs sas

Abrégé

Systems and methods for guiding radiation therapy including providing particle radiation to a region of interest of a subject and receiving volumetric ionizing radiation acoustic imaging (iRAI) data and ultrasound imaging data from the region of in response the particle radiation. Further, from the iRAI data and the ultrasound imaging, a position of the particle radiation in the region of interest is determined, that position being a treatment position of the particle radiation. Further, the systems and methods determine one or more parameters of the particle radiation for adjusting in response to the determination of the position.

Classes IPC  ?

• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• A61B 8/08 - Applications cliniques

Abrégé

Carbonic anhydrase IX (CAIX) and carbonic anhydrase XII (CAXII) binding molecules, bispecific binding molecules formed from the same, and methods of detecting and/or treating regional lymph node metastasis using said bispecific binding molecules.

Classes IPC  ?

• A61K 40/42 - Antigènes associés au cancer
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire

Abrégé

Disclosed herein are engineered T cells with modified SLAMF7 signaling and enhanced T-cell activation. For example, disclosed herein is an engineered T cell, having modified SLAMF7 signaling and enhanced T-cell activation, wherein the T cell comprises a recombinant nucleic acid encoding a transgenic CD319 (SLAMF7) protein, the T cell is genetically modified to overexpress SAP; and/or the T cell is genetically modified to have knocked down tyrosine phosphatase expression. In some embodiments, the transgenic SLAMF7 protein is overexpressed in the engineered T cell, has a mutated or truncated ectodomain with reduced binding to self-ligand, and/or has a mutated ITSM domain to prefer binding by signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) over a tyrosine phosphatase.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/67 - Méthodes générales pour favoriser l'expression

Abrégé

Disclosed herein are chimeric antigen receptors (CARs) with SLAMF7 co-stimulatory domains. For example, disclosed herein is a chimeric antigen receptor (CAR) polypeptide having a signaling peptide, a ligand binding domain, a hinge domain, a transmembrane domain, and an endodomain that comprises a CD3ζ domain and a SLAMF7 co-stimulatory domain. In some embodiments the endodomain further comprises a CD28 co-stimulatory domain, 4-1BB co-stimulatory domain, or a combination thereof.

Classes IPC  ?

• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The present disclosure relates circulating tumor DNA and methods of treating, preventing, and diagnosing cancer. The present disclosure also provides methods of assessing the efficacy of a therapy after cancer diagnosis.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux

Abrégé

Disclosed herein is a method of treating a tumor in a subject that involves a) treating the tumor with an effective amount of radiotherapy: b) treating the subject with an effective amount of a B cell agonist: and c) administering to the subject a 4-1BB agonist. In some embodiments. the 4-1BB agonist is an isolated monoclonal antibody. or antigen binding portion thereof, that specifically binds human CD137 (4-1BB).

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• A61K 38/20 - Interleukines
• A61K 38/21 - Interférons
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure provides methods for treating ULK3-associated cancers, such as multiple myeloma or breast cancer, in subjects in need thereof.

Classes IPC  ?

• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 38/07 - Tétrapeptides

Abrégé

Disclosed are purine derivatives of formulae (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods involving the inventive compounds or compositions for treating and/or preventing cell proliferative diseases including certain cancers of breast, brain, ovarian, lung, colorectal cancer, leukemias, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma and inflammatory and myotonic dystrophy type 1 diseases in a mammal. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of kinases, such as a cyclin-dependent kinases (CDK) (e.g., CDK12/13), and therefore, induce potent antiproliferative and apoptotic effects and/or inhibit transcription in the subject.

Classes IPC  ?

• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/13 - Amines, p. ex. amantadine
• A61K 31/33 - Composés hétérocycliques
• C07D 471/02 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes du système condensé, au moins un cycle étant un cycle à six chaînons avec un atome d'azote, non prévus dans les groupes dans lesquels le système condensé contient deux hétérocycles

Abrégé

Disclosed are substituted purine derivatives of formulae (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods involving the inventive compounds or compositions for treating and/or preventing cell proliferative diseases including certain cancers of breast, brain, ovarian, lung, colorectal cancer, leukemias, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma and inflammatory and myotonic dystrophy type 1 diseases in a mammal. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of kinases, such as a cyclin-dependent kinases (CDK) (e.g., CDK12/13), and degrade some other proteins (including cycK) and therefore, induce potent antiproliferative and apoptotic effects and/or inhibit transcription in the subject.

Classes IPC  ?

• C07D 235/14 - Radicaux substitués par des atomes d'azote
• C07D 487/04 - Systèmes condensés en ortho
• A61P 35/00 - Agents anticancéreux

Produits et services

Promoting the economic development of Pasco County in the State of Florida by coordinating academic, industry, and government research, education, clinical care delivery and entrepreneurship in the fields of healthcare, biotechnology, education, digital innovation, retail and commerce; business consulting services in the field of organizing partnerships between public and private entities; development of public-private partnerships for building shared research or manufacturing facilities, retail, and technology commercialization, namely, business networking, promoting collaboration within the scientific research and medical communities to achieve advances in the field of healthcare; operation services, namely, business management of services provided by others to maintain open spaces and parks; Marketing services; communication services, namely, dissemination of advertising matter; public relations services; business management of property owner’s associations for others; property owner association services, namely, promoting the interests of property owners in a specific community and marketing the community nationwide to prospective new property owners; business management of tenant associations, namely, promoting the interests of real estate and commercial tenants in a specific community and marketing the community to the public and prospective new tenants; Consultancy regarding public relations communication strategies; Real estate sales management; Providing facilities for business meetings; providing a website featuring business information in the field of economic and workforce development, business, partnerships and networking, business collaboration services, and leasing and selling of retail and office spaces for business purposes, all designed to improve, market, promote and protect the shared real estate premises throughout the collaboration of the organization based there Leasing of office space; Leasing of real estate; Leasing or renting of buildings; Real estate service, namely, rental property management; Land leasing; leasing of real estate space, namely, office space, retail space, hotels and dormitories, apartments commercial space, laboratory and research space; Land acquisition services; providing research scholarships; charitable fundraising; operation services, namely, rental property management and management of commercial property and offices; business collaboration services, namely, leasing and rental of offices and office space in the nature of a shared business environment consisting of conference rooms, classrooms and common gathering areas to entrepreneurs, start-ups, existing businesses, academic and research institutions and for the purpose of promoting collaboration to achieve benefits in business networking and business growth Real estate development; Real estate development provided through public and private partnerships; real estate development services in the field of mixed use development comprised of residential, commercial, retail office, and industrial spaces; construction services, namely, construction planning, land development in the nature of planning and laying out of commercial, retail office and industrial buildings, building construction, space planning in the nature of laying out commercial, retail office and industrial buildings, laying out commercial, retail office and industrial buildings, building construction and construction management of park structures, open space structures, residential buildings, transportation buildings and commercial building projects; real estate development services in the field of short-term residential, commercial, retail office, and industrial properties Arranging and conducting of conferences and symposia in the field of medical science; Arranging and conducting of educational conferences in the field of innovation, health and medicine; Arranging and conducting of educational conferences in the field of information science and technology; Education services, namely, providing seminars and symposia in the field of innovation, health and medicine; Providing facilities for educational conventions Hotel accommodation, restaurant and bar services; Hotel accommodation services; Providing facilities for conferences; Providing facilities for exhibitions and conferences; Providing facilities for conferences, exhibitions and meetings; Providing conference facilities; Provision of conference facilities; Providing conference, exhibition and meeting facilities; Provision of conference, exhibition and meeting facilities

Produits et services

Promoting the economic development of Pasco County in the State of Florida by coordinating academic, industry, and government research, education, clinical care delivery and entrepreneurship in the fields of healthcare, biotechnology, education, digital innovation, retail and commerce; business consulting services in the field of organizing partnerships between public and private entities; development of public-private partnerships for building shared research or manufacturing facilities, retail, and technology commercialization, namely, business networking, promoting collaboration within the scientific research and medical communities to achieve advances in the field of healthcare; operation services, namely, business management of services provided by others to maintain open spaces and parks; Marketing services; communication services, namely, dissemination of advertising matter; public relations services; business management of property owner’s associations for others; property owner association services, namely, promoting the interests of property owners in a specific community and marketing the community nationwide to prospective new property owners; business management of tenant associations, namely, promoting the interests of real estate and commercial tenants in a specific community and marketing the community to the public and prospective new tenants; Consultancy regarding public relations communication strategies; Real estate sales management; Providing facilities for business meetings; providing a website featuring business information in the field of economic and workforce development, business, partnerships and networking, business collaboration services, and leasing and selling of retail and office spaces for business purposes, all designed to improve, market, promote and protect the shared real estate premises throughout the collaboration of the organization based there Leasing of office space; Leasing of real estate; Leasing or renting of buildings; Real estate service, namely, rental property management; Land leasing; leasing of real estate space, namely, office space, retail space, hotels and dormitories, apartments commercial space, laboratory and research space; Land acquisition services; providing research scholarships; charitable fundraising; operation services, namely, rental property management and management of commercial property and offices; business collaboration services, namely, leasing and rental of offices and office space in the nature of a shared business environment consisting of conference rooms, classrooms and common gathering areas to entrepreneurs, start-ups, existing businesses, academic and research institutions and for the purpose of promoting collaboration to achieve benefits in business networking and business growth Real estate development; Real estate development provided through public and private partnerships; real estate development services in the field of mixed use development comprised of residential, commercial, retail office, and industrial spaces; construction services, namely, construction planning, land development in the nature of planning and laying out of commercial, retail office and industrial buildings, building construction, space planning in the nature of laying out commercial, retail office and industrial buildings, laying out commercial, retail office and industrial buildings, building construction and construction management of park structures, open space structures, residential buildings, transportation buildings and commercial building projects; real estate development services in the field of short-term residential, commercial, retail office, and industrial properties Arranging and conducting of conferences and symposia in the field of medical science; Arranging and conducting of educational conferences in the field of innovation, health and medicine; Arranging and conducting of educational conferences in the field of information science and technology; Education services, namely, providing seminars and symposia in the field of innovation, health and medicine; Providing facilities for educational conventions Hotel accommodation, restaurant and bar services; Hotel accommodation services; Providing facilities for conferences; Providing facilities for exhibitions and conferences; Providing facilities for conferences, exhibitions and meetings; Providing conference facilities; Provision of conference facilities; Providing conference, exhibition and meeting facilities; Provision of conference, exhibition and meeting facilities

Abrégé

cells that overexpress G6PD.

Classes IPC  ?

• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 38/44 - Oxydoréductases (1)
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 15/86 - Vecteurs viraux
• C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine

Produits et services

Downloadable software in the nature of a mobile application for use in the provision of medical consultations; Downloadable software in the nature of a mobile application for use in the provision of medical consultations and diagnoses in the field of cancer; Downloadable software in the nature of a mobile application for use in the provision of medical consultations and advice for clinical trial placement; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses in the field of cancer; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations and advice for clinical trial placement Software as a service (SAAS) services featuring software for use in the provision of medical consultations; Software as a service (SAAS) services featuring software for use in the provision of medical consultations and diagnoses in the field of cancer; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for use in the provision of medical consultations in the field of cancer; Software as a service (SAAS) services featuring software for use in the provision of medical consultations and advice for clinical trial placement; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations and diagnoses in the field of cancer; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations and advice for clinical trial placement; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses in the field of cancer Online medical consultations rendered in virtual environments; Consulting services in the field of medical care; Consultancy in the field of the medical diagnosis of cancer; Consultancy in the field of the medical treatment of cancer; Consulting services in the field of healthcare; Health care consulting in the field of cancer diagnosis and treatment; Consulting services to health care providers in the field of treating life-changing or life-threatening diseases

Produits et services

Downloadable software in the nature of a mobile application for use in the provision of medical consultations; Downloadable software in the nature of a mobile application for use in the provision of medical consultations and diagnoses in the field of cancer; Downloadable software in the nature of a mobile application for use in the provision of medical consultations and advice for clinical trial placement; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses in the field of cancer; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations and advice for clinical trial placement Software as a service (SAAS) services featuring software for use in the provision of medical consultations; Software as a service (SAAS) services featuring software for use in the provision of medical consultations and diagnoses in the field of cancer; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for use in the provision of medical consultations in the field of cancer; Software as a service (SAAS) services featuring software for use in the provision of medical consultations and advice for clinical trial placement; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations and diagnoses in the field of cancer; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations and advice for clinical trial placement; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses in the field of cancer Online medical consultations rendered in virtual environments; Consulting services in the field of medical care; Consultancy in the field of the medical diagnosis of cancer; Consultancy in the field of the medical treatment of cancer; Consulting services in the field of healthcare; Health care consulting in the field of cancer diagnosis and treatment; Consulting services to health care providers in the field of treating life-changing or life-threatening diseases

Produits et services

Downloadable software in the nature of a mobile application for use in the provision of medical consultations; Downloadable software in the nature of a mobile application for use in the provision of medical consultations and diagnoses in the field of cancer; Downloadable software in the nature of a mobile application for use in the provision of medical consultations and advice for clinical trial placement; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses in the field of cancer; Downloadable computer programs using artificial intelligence (AI) for use in the provision of medical consultations and advice for clinical trial placement Software as a service (SAAS) services featuring software for use in the provision of medical consultations; Software as a service (SAAS) services featuring software for use in the provision of medical consultations and diagnoses in the field of cancer; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for use in the provision of medical consultations in the field of cancer; Software as a service (SAAS) services featuring software for use in the provision of medical consultations and advice for clinical trial placement; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations and diagnoses in the field of cancer; Providing temporary use of non-downloadable cloud-based software for use in the provision of medical consultations and advice for clinical trial placement; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for use in the provision of medical consultations and diagnoses in the field of cancer Online medical consultations rendered in virtual environments; Consulting services in the field of medical care; Consultancy in the field of the medical diagnosis of cancer; Consultancy in the field of the medical treatment of cancer; Consulting services in the field of healthcare; Health care consulting in the field of cancer diagnosis and treatment; Consulting services to health care providers in the field of treating life-changing or life-threatening diseases

Abrégé

The present disclosure provides compounds useful in treating medical disorders, more particular inhibitors of glutathione S-transferase zeta 1 (GSTZ1) which are useful in treating cancers in subjects in need thereof. Compositions comprising said compounds and methods of making and using said compounds are also provided.

Classes IPC  ?

• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
• C07D 241/44 - Benzopyrazines avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone de l'hétérocycle
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

An example computer-implemented method for determining patient-specific tumor dynamics is described herein. The method includes receiving an image of a tissue sample that includes a distribution of tumor cells and non-tumor cells; applying a spatial correlation function to the image; and obtaining a power spectral density of the spatial correlation function of the image. The method also includes fitting the power spectral density of the spatial correlation function of the image to the power spectrum of a reaction-diffusion model; and inferring a patient-specific tumor-dynamic coefficient based on the reaction-diffusion model of cancer.

Classes IPC  ?

• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
• G06T 7/00 - Analyse d'image

Abrégé

Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill cancers. As with other CARs, the disclosed CAR polypeptides contain an ectodomain that contains a binding domain, a hinge domain, a transmembrane (TM) domain, and an endodomain that contains a signaling region. Unlike other CARs, however, the endodomain of the disclosed CAR polypeptides contains an intracellular domain of an NK cell receptor and does not require the signaling domain from CD3 zeta (CD3ζ). Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

Disclosed herein are immune effector cells for use in adoptive cell transfer that have chemically- or genetically-inhibited PDHB (Pyruvate dehydrogenase E1 subunit beta) expression or activity. Also disclosed are methods of inhibiting or ablating PDHB expression in immune effector cells ex vivo and methods of using these cells to treat subjects with cancer. In some embodiments, the immune effector cells are further treated with a TIMS inhibitor or genetically engineered to ablate TIM3 expression. In some embodiments, the immune effector cells are further treated with a LAGS inhibitor or genetically engineered to ablate LAG3 expression. In some cases, the PDHB gene is disrupted by insertion of the gene encoding the chimeric receptor into the PDHB gene loci of the cell. Therefore, disclosed herein is a chimeric cell expressing a chimeric receptor.

Classes IPC  ?

• A61K 40/30 - Immunothérapie cellulaire caractérisée par l’expression recombinante de molécules spécifiques dans les cellules du système immunitaire
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/42 - Antigènes associés au cancer
• C12N 9/22 - Ribonucléases
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

201Tl to visualize any potassium ion loss in the cochlea of the patient which can contribute to auditory disorders such as hearing loss. This non-invasive technique represents a new method for auditory diagnoses by measurement of cochlear properties which can aid in the development of new therapeutics for auditory disorders.

Classes IPC  ?

• A61B 6/03 - Tomographie informatisée
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
• A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes

Abrégé

Disclosed are modified DAP12 and methods of their use for enhancing immune responses and for treating cancer.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 40/19 - Cellules dendritiques
• A61K 40/24 - Cellules présentatrices d’antigènes [APC]
• A61K 40/42 - Antigènes associés au cancer
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 5/0784 - Cellules dendritiquesLeurs progéniteurs

Abrégé

Disclosed are methods for reducing the immunosuppressive effect of myelin derived suppressor cells in adoptive cell therapy.

Classes IPC  ?

• A61K 40/42 - Antigènes associés au cancer
• A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
• A61K 31/52 - Purines, p. ex. adénine
• A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
• A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
• A61K 31/708 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique ayant des groupes oxo liés directement au système cyclique purine, p. ex. guanosine, acide guanylique
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]

Abrégé

Disclosed herein are immune effector cells that are expanded and enriched for NKG2D expression and genetically modified to express chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill CD33-expressing and/or CD123-expressing cancers. In some embodiments, the immune effector cells are gamma-delta (γδ) T cells, Natural Killer (NK) cells, or a combination thereof.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61P 35/00 - Agents anticancéreux
• C07K 14/54 - Interleukines [IL]
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

Disclosed are methods of using cell-free DNA (cfDNA) methylation for the detection, typing, and grading of cancer.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

Sotorasib augments the KRAS-G12C mutant cancer cells response to TNFα by Increasing TNFR1 surface expression, which in turn upregulates TNFα and IFNy down-stream target genes and ultimately enhances cancer cell death. In TACE-dependent mechanism, Sotorasib inhibited TNFR1 shedding off the KRAS-G12C mutant cancer cells. Additionally, Sotorasib significantly promotes the expansion of tumor infiltrating lymphocytes (TILs). In, addition, it generates a “hot” tumor microenvironment with strikingly augmented T cell effector phenotype. These results suggest that sotorasib regulation of TNFa and IFNy plays a crucial role in generating a more immune active tumor microenvironment. Consistently, sotorasib combined with CAR-T adoptive cell transfer and anti-PD1 treatment enhanced their anti-tumor effect. Therefore, disclosed herein is a method for treating KRAS-G12C mutant cancer in a subject, the method involving adoptively transferring an effective amount of autologous or allogeneic immune effector cells (T cells) to the subject in combination with a KRAS-G12C inhibitor

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Disclosed are bispecific molecules, referred to herein as ubiquibodies, that are able to ubiquitinate target cell surface receptors on a target cell. The ubiquibodies can be engineered from fusion polypeptides comprising 1) variable domains of antibodies that specifically bind a target cell surface receptor and 2) variable domains of antibodies that specifically bind a transmembrane E3 ubiquitin ligase (TMUL). Either or both components of the ubiquibodies can also be engineered from non-antibody scaffolds including but not limited to nanobodies, monobodies, cyclic peptides, small molecules, and designed ankyrin repeat proteins (Darpins).

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Disclosed are long non-coding RNAs (IncRNAS) for TROLL-8. It is shown herein that IncRNAs TROLL-8, is a suitable target for cancer therapies and can be used to make prognostic determinations about a cancer. Specifically, the disclosure provides a method of assessing tumor grade and/or progression of a cancer and/or metastasis in a subject comprising obtaining a tissue sample from a subject and measuring the expression level of the long non-coding RNA for TROLL-8; wherein the higher the level of IncRNA for TROLL-8, the greater the severity and/or invasiveness of the tumor is indicated. Further disclosed is a method of assessing the efficacy of a cancer treatment regimen administered to a subject, the method comprising measuring the expression level of the long non-coding RNA for TROLL-8 in a tissue sample from the subject relative to a control.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• A61K 38/45 - Transférases (2)
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Produits et services

Business consulting services; New business venture development and formation consulting services; Business consulting services for start-up companies; Business management consultancy; Managing the ordering and hiring of additional staff for others; Employment staffing consultation services; Business organization and operation consultancy; Business incubator and accelerator services; Business incubator and accelerator services, namely, consultancy and advisory services regarding business strategy, business analysis, business development, and business planning services; Business incubator and accelerator services, namely, providing work space containing business equipment to emerging and start-up companies; Business networking services; Operation of a business for others, namely, start up businesses; Arranging and conducting competitions for participants to compete for seed capital, financial support, business support, technology support, and related funding and business mentoring, to implement business plans and facilitate business activities; arranging and conducting competitions for participants to compete for seed capital, financial support, business support, technology support, and related funding and business mentoring, to facilitate the execution of business plans designed to address community and global challenges in a wide variety of fields, including technology, business, science, education, food supply, medicine, health, genomics, global issues, economics, environmental issues, sustainability, politics, the humanities, leadership, public policy, and social and cultural issues; promoting the exchange of information and resources within the scientific, research, education, and business communities to address community and global challenges in a wide variety of fields, and to implement business solutions to achieve advancements at the community and global levels; promoting collaboration within the education, scientific, research, and business communities to achieve societal advancements on a global scale; promoting public awareness of community and global challenges by providing forums for individuals and entrepreneurs to present ideas, innovations, and business plans designed to address specific challenges at the global or community levels; promoting public awareness of community and global challenges by providing live forums for participants to present ideas, innovations, and business plans designed to address specific challenges at the global or community levels, for review and discussion among a live audience and panel of leaders, innovators, and experts in a wide variety of fields; promoting public awareness of initiatives, programs, developments, ideas, innovations, and discoveries that address community and global challenges, via community outreach campaigns and events, and global outreach campaigns and events; organization of conferences, demonstrations, meetings, symposia, and events for business purposes; promoting public awareness of the need for business, community, educational, and institutional collaboration to address community and global challenges; arranging and conducting live forums and workshops for participants to collaborate, brainstorm, demonstrate, develop, and promote new and innovative ideas, products, and services to address community and global challenges; promoting public awareness of community and global challenges; providing management consultation and administrative support related to the organization and implementation of community outreach events, conferences, summits, and symposia; arranging and conducting conferences, demonstrations, meetings, symposia, summits, and events for business purposes in the fields of science, technology, health, education, medicine, business, global issues, public policy, sustainability, environmental issues, innovation, entrepreneurship, venture funding, social impact, business development, and business networking; providing an in-person business forum in the fields of science, technology, health, medicine, education, energy, business, global issues, public policy, sustainability, the environment, innovation, entrepreneurship, venture funding, social impact, business development, and business networking; promotional sponsorship of competitions to address community and global challenges; promotional sponsorship of individuals and entities selected to implement business plans to address community and global challenges; association services, namely, promoting the interests of academic institutions, governmental organizations, non-governmental organizations (NGOs), and corporations in the fields of innovation, education, business, and public policy Incubation services for businesses, namely, providing financing to start-ups and existing businesses; Venture capital financing and funding services for businesses; Advisory services in the field of business funding and venture capital financing; Organizing economic development fundraising programs for the benefit of start-up and existing businesses; Business incubator services, namely, a startup studio facilitating financing and equity capital investment to early stage entrepreneurs and enterprises Providing coaching and mentoring services in the field of entrepreneurship, business, personal performance, and professional performance Providing facilities for scientific research; Providing specialized facilities for medical research laboratories; Providing specialized facilities for medical and scientific research in the field of cancer treatment and diagnosis

Produits et services

Business consulting services; New business venture development and formation consulting services; Business consulting services for start-up companies; Business management consultancy; Managing the ordering and hiring of additional staff for others; Employment staffing consultation services; Business organization and operation consultancy; Business incubator and accelerator services; Business incubator and accelerator services, namely, consultancy and advisory services regarding business strategy, business analysis, business development, and business planning services; Business incubator and accelerator services, namely, providing work space containing business equipment to emerging and start-up companies; Business networking services; Operation of a business for others, namely, start up businesses; Arranging and conducting competitions for participants to compete for seed capital, financial support, business support, technology support, and related funding and business mentoring, to implement business plans and facilitate business activities; arranging and conducting competitions for participants to compete for seed capital, financial support, business support, technology support, and related funding and business mentoring, to facilitate the execution of business plans designed to address community and global challenges in a wide variety of fields, including technology, business, science, education, food supply, medicine, health, genomics, global issues, economics, environmental issues, sustainability, politics, the humanities, leadership, public policy, and social and cultural issues; promoting the exchange of information and resources within the scientific, research, education, and business communities to address community and global challenges in a wide variety of fields, and to implement business solutions to achieve advancements at the community and global levels; promoting collaboration within the education, scientific, research, and business communities to achieve societal advancements on a global scale; promoting public awareness of community and global challenges by providing forums for individuals and entrepreneurs to present ideas, innovations, and business plans designed to address specific challenges at the global or community levels; promoting public awareness of community and global challenges by providing live forums for participants to present ideas, innovations, and business plans designed to address specific challenges at the global or community levels, for review and discussion among a live audience and panel of leaders, innovators, and experts in a wide variety of fields; promoting public awareness of initiatives, programs, developments, ideas, innovations, and discoveries that address community and global challenges, via community outreach campaigns and events, and global outreach campaigns and events; organization of conferences, demonstrations, meetings, symposia, and events for business purposes; promoting public awareness of the need for business, community, educational, and institutional collaboration to address community and global challenges; arranging and conducting live forums and workshops for participants to collaborate, brainstorm, demonstrate, develop, and promote new and innovative ideas, products, and services to address community and global challenges; promoting public awareness of community and global challenges; providing management consultation and administrative support related to the organization and implementation of community outreach events, conferences, summits, and symposia; arranging and conducting conferences, demonstrations, meetings, symposia, summits, and events for business purposes in the fields of science, technology, health, education, medicine, business, global issues, public policy, sustainability, environmental issues, innovation, entrepreneurship, venture funding, social impact, business development, and business networking; providing an in-person business forum in the fields of science, technology, health, medicine, education, energy, business, global issues, public policy, sustainability, the environment, innovation, entrepreneurship, venture funding, social impact, business development, and business networking; promotional sponsorship of competitions to address community and global challenges; promotional sponsorship of individuals and entities selected to implement business plans to address community and global challenges; association services, namely, promoting the interests of academic institutions, governmental organizations, non-governmental organizations (NGOs), and corporations in the fields of innovation, education, business, and public policy Incubation services for businesses, namely, providing financing to start-ups and existing businesses; Venture capital financing and funding services for businesses; Advisory services in the field of business funding and venture capital financing; Organizing economic development fundraising programs for the benefit of start-up and existing businesses; Business incubator services, namely, a startup studio facilitating financing and equity capital investment to early stage entrepreneurs and enterprises Providing coaching and mentoring services in the field of entrepreneurship, business, personal performance, and professional performance Providing facilities for scientific research; Providing specialized facilities for medical research laboratories; Providing specialized facilities for medical and scientific research in the field of cancer treatment and diagnosis

Produits et services

Business consulting services; New business venture development and formation consulting services; Business consulting services for start-up companies; Business management consultancy; Managing the ordering and hiring of additional staff for others; Employment staffing consultation services; Business organization and operation consultancy; Business incubator and accelerator services; Business incubator and accelerator services, namely, consultancy and advisory services regarding business strategy, business analysis, business development, and business planning services; Business incubator and accelerator services, namely, providing work space containing business equipment to emerging and start-up companies; Business networking services; Operation of a business for others, namely, start up businesses; Arranging and conducting competitions for participants to compete for seed capital, financial support, business support, technology support, and related funding and business mentoring, to implement business plans and facilitate business activities; arranging and conducting competitions for participants to compete for seed capital, financial support, business support, technology support, and related funding and business mentoring, to facilitate the execution of business plans designed to address community and global challenges in a wide variety of fields, including technology, business, science, education, food supply, medicine, health, genomics, global issues, economics, environmental issues, sustainability, politics, the humanities, leadership, public policy, and social and cultural issues; promoting the exchange of information and resources within the scientific, research, education, and business communities to address community and global challenges in a wide variety of fields, and to implement business solutions to achieve advancements at the community and global levels; promoting collaboration within the education, scientific, research, and business communities to achieve societal advancements on a global scale; promoting public awareness of community and global challenges by providing forums for individuals and entrepreneurs to present ideas, innovations, and business plans designed to address specific challenges at the global or community levels; promoting public awareness of community and global challenges by providing live forums for participants to present ideas, innovations, and business plans designed to address specific challenges at the global or community levels, for review and discussion among a live audience and panel of leaders, innovators, and experts in a wide variety of fields; promoting public awareness of initiatives, programs, developments, ideas, innovations, and discoveries that address community and global challenges, via community outreach campaigns and events, and global outreach campaigns and events; organization of conferences, demonstrations, meetings, symposia, and events for business purposes; promoting public awareness of the need for business, community, educational, and institutional collaboration to address community and global challenges; arranging and conducting live forums and workshops for participants to collaborate, brainstorm, demonstrate, develop, and promote new and innovative ideas, products, and services to address community and global challenges; promoting public awareness of community and global challenges; providing management consultation and administrative support related to the organization and implementation of community outreach events, conferences, summits, and symposia; arranging and conducting conferences, demonstrations, meetings, symposia, summits, and events for business purposes in the fields of science, technology, health, education, medicine, business, global issues, public policy, sustainability, environmental issues, innovation, entrepreneurship, venture funding, social impact, business development, and business networking; providing an in-person business forum in the fields of science, technology, health, medicine, education, energy, business, global issues, public policy, sustainability, the environment, innovation, entrepreneurship, venture funding, social impact, business development, and business networking; promotional sponsorship of competitions to address community and global challenges; promotional sponsorship of individuals and entities selected to implement business plans to address community and global challenges; association services, namely, promoting the interests of academic institutions, governmental organizations, non-governmental organizations (NGOs), and corporations in the fields of innovation, education, business, and public policy Incubation services for businesses, namely, providing financing to start-ups and existing businesses; Venture capital financing and funding services for businesses; Advisory services in the field of business funding and venture capital financing; Organizing economic development fundraising programs for the benefit of start-up and existing businesses; Business incubator services, namely, a startup studio facilitating financing and equity capital investment to early stage entrepreneurs and enterprises Providing coaching and mentoring services in the field of entrepreneurship, business, personal performance, and professional performance Providing facilities for scientific research; Providing specialized facilities for medical research laboratories; Providing specialized facilities for medical and scientific research in the field of cancer treatment and diagnosis

Produits et services

Business consulting services; New business venture development and formation consulting services; Business consulting services for start-up companies; Business management consultancy; Managing the ordering and hiring of additional staff for others; Employment staffing consultation services; Business organization and operation consultancy; Business incubator and accelerator services; Business incubator and accelerator services, namely, consultancy and advisory services regarding business strategy, business analysis, business development, and business planning services; Business incubator and accelerator services, namely, providing work space containing business equipment to emerging and start-up companies; Business networking services; Operation of a business for others, namely, start up businesses; Arranging and conducting competitions for participants to compete for seed capital, financial support, business support, technology support, and related funding and business mentoring, to implement business plans and facilitate business activities; arranging and conducting competitions for participants to compete for seed capital, financial support, business support, technology support, and related funding and business mentoring, to facilitate the execution of business plans designed to address community and global challenges in a wide variety of fields, including technology, business, science, education, food supply, medicine, health, genomics, global issues, economics, environmental issues, sustainability, politics, the humanities, leadership, public policy, and social and cultural issues; promoting the exchange of information and resources within the scientific, research, education, and business communities to address community and global challenges in a wide variety of fields, and to implement business solutions to achieve advancements at the community and global levels; promoting collaboration within the education, scientific, research, and business communities to achieve societal advancements on a global scale; promoting public awareness of community and global challenges by providing forums for individuals and entrepreneurs to present ideas, innovations, and business plans designed to address specific challenges at the global or community levels; promoting public awareness of community and global challenges by providing live forums for participants to present ideas, innovations, and business plans designed to address specific challenges at the global or community levels, for review and discussion among a live audience and panel of leaders, innovators, and experts in a wide variety of fields; promoting public awareness of initiatives, programs, developments, ideas, innovations, and discoveries that address community and global challenges, via community outreach campaigns and events, and global outreach campaigns and events; organization of conferences, demonstrations, meetings, symposia, and events for business purposes; promoting public awareness of the need for business, community, educational, and institutional collaboration to address community and global challenges; arranging and conducting live forums and workshops for participants to collaborate, brainstorm, demonstrate, develop, and promote new and innovative ideas, products, and services to address community and global challenges; promoting public awareness of community and global challenges; providing management consultation and administrative support related to the organization and implementation of community outreach events, conferences, summits, and symposia; arranging and conducting conferences, demonstrations, meetings, symposia, summits, and events for business purposes in the fields of science, technology, health, education, medicine, business, global issues, public policy, sustainability, environmental issues, innovation, entrepreneurship, venture funding, social impact, business development, and business networking; providing an in-person business forum in the fields of science, technology, health, medicine, education, energy, business, global issues, public policy, sustainability, the environment, innovation, entrepreneurship, venture funding, social impact, business development, and business networking; promotional sponsorship of competitions to address community and global challenges; promotional sponsorship of individuals and entities selected to implement business plans to address community and global challenges; association services, namely, promoting the interests of academic institutions, governmental organizations, non-governmental organizations (NGOs), and corporations in the fields of innovation, education, business, and public policy Incubation services for businesses, namely, providing financing to start-ups and existing businesses; Venture capital financing and funding services for businesses; Advisory services in the field of business funding and venture capital financing; Organizing economic development fundraising programs for the benefit of start-up and existing businesses; Business incubator services, namely, a startup studio facilitating financing and equity capital investment to early stage entrepreneurs and enterprises Providing coaching and mentoring services in the field of entrepreneurship, business, personal performance, and professional performance Providing facilities for scientific research; Providing specialized facilities for medical research laboratories; Providing specialized facilities for medical and scientific research in the field of cancer treatment and diagnosis

Abrégé

Disclosed herein is a method for preventing or reversing CAR-T cell resistance and/or radioresistance in a relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL) of a subject, that involves assaying a sample from the subject for mRNA sequences of genes with roles in DNA damage, apoptosis, immune activation, and/or c-MYC signaling; detecting aberrant splicing in one or more of the mRNA sequences; and administering to the subject an antisense oligonucleotide (ASO) that prevents the aberrant splicing.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.

Classes IPC  ?

• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
• A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
• A61K 31/45 - Pipéridines non condensées, p. ex. pipérocaïne ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cycloheximide
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs

Abrégé

Disclosed are inhibitors for the β-catenin/T-cell factor interaction. The inhibitors are selective for β-catenin/T-cell factor over β-catenin/phosphocadherin, and β-catenin/phosphoAPC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Classes IPC  ?

• C07K 5/113 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p. ex. Asp, Glu, Asn
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 35/00 - Agents anticancéreux

Abrégé

Disclosed are anti-syndecan binding protein (SDCBP) binding molecules and methods for using anti-SDCBP in the treatment of cancer, including, but not limited to endometriosis or ovarian cancer.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux

Abrégé

Disclosed are methods for expanding tumor infiltrating lymphocytes (TILs) and driving TILs towards a memory T cell phenotype. Also disclosed is the creation of a mouse model to investigate adoptive cell therapy using TILs.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61P 35/00 - Agents anticancéreux
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

Disclosed herein are small molecule pyrin-domain targeted NLRP3 inflammasome inhibitors.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• C07D 213/85 - Nitriles en position 3
• C07D 277/56 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
• C07D 277/68 - Benzothiazoles avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement en position 2
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou

Abrégé

Disclosed are TCRalpha and TCRbeta chains specific for New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and their use in the detection of cytolytic function by immune cells or secretion inflammatory cytokines by the modified immune cell and treatment of said cancer by administration of a modified immune cell and/or anti-NY-ESO-1 ImmTAC comprising a TCR specific for NY-ESO-1.

Classes IPC  ?

• A61K 40/42 - Antigènes associés au cancer
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/32 - Récepteurs des lymphocytes T [TCR]

Abrégé

Disclosed herein is the engineering of a new class of chimeric Notch activating proteins (NAPs) that are used as tissue- specific activators of Notch signaling. The disclosed bispecific NAPs create the tension necessary to activate Notch by crosslinking it with targeted internalized biomarkers on adjacent cells. In some embodiments, it includes loss-of-function DLL4 mutants Notch signaling rescued by NAPs.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C07K 14/485 - Facteur de croissance de l'épiderme [EGF], c.-à-d. urogastrone
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs

Abrégé

Disclosed are compositions and methods for the treatment of cancer through immune checkpoints inhibitors. CD112R is being presented as a new immune checkpoint inhibitor with high potential in cancer immunotherapy and cancer prognosis. Also disclosed herein are methods of treating cancer in a subject by administering an isolated receptor or target binding molecule such as CD112R extracellular domain variant that binds CD112 or administering a pharmaceutical composition comprising CD112R extracellular domain variant to a subject with a cancer.

Classes IPC  ?

• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 35/00 - Agents anticancéreux
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Disclosed herein are compositions and methods of treating cancer in a subject by administering a chimeric receptor such as CD112R extracellular domain variant that binds CD112 or administering a pharmaceutical composition comprising CD112R extracellular domain variant as a chimeric antigen receptor and/or a chimeric switch receptor to a subject with a cancer.

Classes IPC  ?

• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire

Abrégé

Disclosed are methods for the detection and treatment of leptomeningeal metastasis (LM).

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Disclosed are methods of isolating and expanding tumor infiltrating lymphocytes (TILs) from cerebrospinal fluid and the use of said TILs in the treatment of Leptomeningeal disease.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/30 - NerfsCerveauYeuxCellules cornéennesLiquide céphalorachidienCellules souches neuronalesCellules précurseurs neuronalesCellules glialesOligodendrocytesCellules de SchwannAstrogliesAstrocytesPlexus choroïdeTissu de moelle épinière

Abrégé

Dual-chimeric antigen receptor (CAR) cell systems are disclosed that can be used with adoptive cell transfer to target and kill cancers expressing tumor antigens (“TA”) that are also expressed on healthy hematopoietic cells. In some embodiments, the dual CAR cell expresses a first CAR polypeptide that contains in an ectodomain a binding agent that can selectively bind CD83 on CD83-expressing cancer cells (“anti-CD83 binding agent”), and a second CAR polypeptide that contains in an ectodomain an antigen-binding agent that can bind a second tumor antigen that is expressed on both the cancer and healthy hematopoietic cells (“anti-TA binding agent”), such as CD33, CLEC12A, CD123, or FLT3.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Skin cancer is the most common form of malignancy in humans, with significant associated morbidity and cost, and steadily increasing incidence. Since it is now well established that UV-damaged epidermal keratinocytes in intact skin can harbor on the order of 5 mutations/Mb, this raises the possibility of using this mutational burden as a dosimeter of UV-induced damage and potentially skin cancer risk. In particular, sampling normal skin for biomarkers of UV exposure can lead to better understanding of the genomic alterations associated with initiation of skin cancer, which ultimately will aid in stratifying risk of skin cancer development, determination of effectiveness of current prevention methods, and better targeted therapies. Disclosed herein are devices and systems for interrogation of normal non-lesional skin to extract epidermal DNA for analysis. This approach can be generalized to any epithelial surface including in the oral cavity, gastrointestinal, or genitourinary tracts.

Classes IPC  ?

• A61B 10/02 - Instruments pour prélever des échantillons cellulaires ou pour la biopsie
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Produits et services

Promoting the economic development of Pasco County in the State of Florida by coordinating academic, industry, and government research, education, clinical care delivery and entrepreneurship in the fields of healthcare, biotechnology, education, digital innovation, retail and commerce; business consulting services in the field of organizing partnerships between public and private entities; development of public-private partnerships for building shared research or manufacturing facilities, retail, and technology commercialization, namely, business networking, promoting collaboration within the scientific research and medical communities to achieve advances in the field of healthcare; operation services, namely, business management of services provided by others to maintain open spaces and parks; Marketing services; communication services, namely, dissemination of advertising matter; public relations services; business management of property owner’s associations for others; property owner association services, namely, promoting the interests of property owners in a specific community and marketing the community nationwide to prospective new property owners; business management of tenant associations, namely, promoting the interests of real estate and commercial tenants in a specific community and marketing the community to the public and prospective new tenants; Consultancy regarding public relations communication strategies; Real estate sales management; providing a website featuring business information in the field of economic and workforce development, business, partnerships and networking, business collaboration services, and leasing and selling of retail and office spaces for business purposes, all designed to improve, market, promote and protect the shared real estate premises throughout the collaboration of the organization based there; Providing facilities for business meetings Leasing of office space; Leasing of real estate; Leasing or renting of buildings; Real estate service, namely, rental property management; Land leasing; leasing of real estate space, namely, office space, retail space, hotels and dormitories, apartments commercial space, laboratory and research space; Land acquisition services; providing research scholarships; charitable fundraising; operation services, namely, rental property management and management of commercial property and offices; business collaboration services, namely, leasing and rental of offices and office space in the nature of a shared business environment consisting of conference rooms, classrooms and common gathering areas to entrepreneurs, start-ups, existing businesses, academic and research institutions and for the purpose of promoting collaboration to achieve benefits in business networking and business growth Real estate development; Real estate development provided through public and private partnerships; real estate development services in the field of short-term residential, commercial, retail office, and industrial properties; real estate development services in the field of mixed use development comprised of residential, commercial, retail office, and industrial spaces; construction services, namely, construction planning, land development in the nature of planning and laying out of commercial, retail office and industrial buildings, building construction, space planning in the nature of laying out commercial, retail office and industrial buildings, laying out commercial, retail office and industrial buildings, building construction and construction management of park structures, open space structures, residential buildings, transportation buildings and commercial building projects Arranging and conducting of conferences and symposia in the field of medical science; Arranging and conducting of educational conferences in the field of innovation, health and medicine; Arranging and conducting of educational conferences in the field of information science and technology; Education services, namely, providing seminars and symposia in the field of innovation, health and medicine; Providing facilities for educational conventions Hotel accommodation, restaurant and bar services; Hotel accommodation services; Providing facilities for conferences; Providing facilities for exhibitions and conferences; Providing facilities for conferences, exhibitions and meetings; Providing conference facilities; Provision of conference facilities; Provision of conference, exhibition and meeting facilities; Providing conference, exhibition and meeting facilities

Abrégé

Lack of persistence and sensitivity to apoptosis and or activation induced cell death are mechanisms that contribute to cellular immunotherapy failure. Genetically engineering cell therapies to overcome these mechanisms should improve cell based immutherapy efficacy. Therefore, disclosed herein are mutant Bcl-XL (mBcl-XL) variants with serine 62 to alanine mutation (D62A) and or in combination with single or all possible combinations of lysine to alanine mutations at lysines 16, 20, 87, 157, 205, or 233. These variants can be expressed alone or co-expressed with other recombinant or wild type proteins e.g. chimeric antigen receptors, chimeric endocrine receptors, or other genes using viral encoded transduction or physical gene delivery methods like electroporation.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61P 35/00 - Agents anticancéreux
• C12N 15/86 - Vecteurs viraux

Abrégé

Disclosed are compositions and methods related to anti-ACAT1 binding molecules that preferentially bind glycosylated ACAT1.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux

Produits et services

Downloadable electronic publications in the nature of brochures and newsletters in the field of cancer care and prevention of cancer Printed publications, namely, brochures and newsletters in the field of cancer care and prevention of cancer Providing on-line publications in the nature of articles in the field of cancer and cancer care; Providing a website featuring blogs and non-downloadable publications in the nature of articles in the field(s) of cancer and cancer care

Abrégé

The present disclosure relates to compounds, compositions, and methods for treating cancers mediated by aberrant Histone Acetyltransferase p300 (EP300) and/or CREB-Binding Protein (CBP) activity.

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles

Produits et services

Conducting of business conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Conducting of educational conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Arranging and conducting of conferences in the field of healthcare, medical research, cancer care, life sciences, and education

Produits et services

Pre-recorded record albums featuring music

Produits et services

Fans for personal use, non-electric Tumblers for use as drinking glasses Textile workout towels T-shirts; Shirts; Clothing jackets; Outer jackets; Sports jackets; Shell jackets; Rain jackets; Headbands Entertainment services, namely, providing podcasts in the field of immunotherapy

Produits et services

Conducting of business conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Conducting of educational conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Arranging and conducting of conferences in the field of healthcare, medical research, cancer care, life sciences, and education

Produits et services

Fans for personal use, non-electric Tumblers for use as drinking glasses Textile workout towels T-shirts; Shirts; Clothing jackets; Outer jackets; Sports jackets; Shell jackets; Rain jackets; Headbands Entertainment services, namely, providing podcasts in the field of immunotherapy

Abrégé

A system may receive sequencing data for a cell sample, the cell sample comprising a plurality of cells. A system may receive an image of the cell sample. A system may analyze the image to determine a plurality of respective cell cycle states for the plurality of cells in the cell sample. A system may integrate the sequencing data with the image using the plurality of respective cell cycle states.

Classes IPC  ?

• G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
• G06T 7/00 - Analyse d'image
• G06V 10/62 - Extraction de caractéristiques d’images ou de vidéos relative à une dimension temporelle, p. ex. extraction de caractéristiques axées sur le tempsSuivi de modèle
• G06V 10/762 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant le regroupement, p. ex. de visages similaires sur les réseaux sociaux
• G06V 10/77 - Traitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source
• G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides

Abrégé

Various implementations include a system for coupling a needle to a port. The system includes a port and a needle. The port includes a reservoir and a lock box disposed within the cavity and defining a lock opening. The reservoir includes a membrane and a base coupled to the membrane, which together define a cavity. The reservoir is configured to be implanted under the skin of a person. The needle defines a lumen extending along a needle longitudinal axis. The needle includes a key disposed within the lumen. The key is movable from a first position to a second position. A portion of the key extends further in a radially outward direction in the second position than in the first position. A distal end of the needle is disposable within the lock opening such that the key is couplable to the lock box when in the second position.

Classes IPC  ?

• A61M 39/02 - Voies d'accès

Abrégé

As disclosed herein, inhibition of the ornithine decarboxylase 1-driven pathway can restore immunotherapeutic efficacy in lung cancer with lost STK11 function. Therefore, disclosed herein are compositions and methods for treating a lung cancer in a subject using an ornithine decarboxylase (ODC) inhibitor, such as difluromethylornithine. In particular, disclosed is a method for using an ODC inhibitor to sensitize a lung cancer to immunotherapy. The method can involve assaying the subject for STK11 function. The method can also involve treating the subject with an immunotherapy, such as anti-PD-1/PD-L1 immunotherapy.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

Tumor infiltrating lymphocytes (TILs) are immune cells that have left the bloodstream and migrated into a tumor. TILs have been used in autologous adoptive transfer therapy for the treatment of cancer. Disclosed are methods for rapidly expanding tumor infiltrating lymphocytes using digested tumor cells. Further, wherein the expanded TIL population also has enriched tumor specificity.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 9/22 - Ribonucléases
• C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p. ex. hyaluronidase, invertase, amylase
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine

Abrégé

This disclosure provides reagents and processes for the synthesis of organic compounds, more particularly reagents and processes for the asymmetric synthesis of sulfur (VI) containing organic compounds.

Classes IPC  ?

• C07C 311/02 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé
• C07C 303/40 - Préparation d'esters ou d'amides d'acides sulfuriquesPréparation d'acides sulfoniques ou de leurs esters, halogénures, anhydrides ou amides d'amides d'acides sulfoniques par des réactions n'impliquant pas la formation de groupes sulfonamide

Abrégé

The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 40/19 - Cellules dendritiques
• A61K 40/24 - Cellules présentatrices d’antigènes [APC]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux

Abrégé

Disclosed herein are non-viral methods to ablate FOXP1 in T cells while effectively expressing chimeric receptors. Therefore, disclosed herein is a chimeric cell expressing a chimeric receptor, wherein the chimeric receptor is encoded by a transgene, and wherein the transgene is inserted in the genome of the cell at a location that disrupts expression or activity of an endogenous FOXP1 protein.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer

Abrégé

The present disclosure described compounds of Formula I, or pharmaceutically acceptable salts or derivatives thereof, which are degraders of TAF1. Methods of using the compounds in the treatment of medical disorders, such as cancers, are also provided.

Classes IPC  ?

• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61K 31/12 - Cétones
• A61K 31/404 - Indoles, p. ex. pindolol
• A61K 31/33 - Composés hétérocycliques

Abrégé

Systems and methods for predicting hematological conditions using methylation data are described herein. An example computer-implemented method includes: receiving patient data associated with a blood specimen from a subject, the patient data including fluctuating methylation clock (FMC) data; inputting the FMC data into a trained machine learning model; and predicting, using the trained machine learning model, a hematological condition in the subject.

Classes IPC  ?

• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• G16B 20/10 - Ploïdie ou détection du nombre de copies
• G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

Disclosed are compositions and methods for targeted treatment of infections and cancers expressing cancers. In particular, tumor infiltrating lymphocytes (TILs) are genetically engineered to express chimeric antigen receptor (CAR) polypeptides to produce CAR-TILs that can be used with adoptive cell transfer to target, penetrate, and kill solid tumor masses. Therefore, also disclosed are methods of providing an immunotherapy in a subject with an infection or cancer that involves adoptive transfer of the disclosed CAR-TILs.

Classes IPC  ?

• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

The present disclosure provides processes for the synthesis of withanolides such as Withanolide A and Withanolide D.

Classes IPC  ?

• C07J 71/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène condensé avec un hétérocycle
• C07J 9/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de plus de deux atomes de carbone, p. ex. cholane, cholestane, coprostane
• C07J 33/00 - Stéroïdes normaux ayant un hétérocycle contenant du soufre non condensé ou condensé en spiro avec le squelette du cyclopenta[a]hydrophénanthrène

Abrégé

The present invention concerns materials and methods for identifying and classifying pancreatic ductal adenocarcinoma (PDAC) precursors or intraductal papillary mucinous neoplasm (IPMN) using messenger RNAs, microRNAs, long non-coding RNAs, radiomic features, radiologic measures of abdominal/visceral obesity, and combinations thereof, as diagnostic markers for integration with clinical management and interventions for personalized care.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Produits et services

Conducting of business conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Conducting of educational conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Arranging and conducting of conferences in the field of healthcare, medical research, cancer care, life sciences, and education Providing health care, medical information and counseling in the field of cancer; providing medical screening and diagnostic services with use of patient scanning equipment; providing an online computer database featuring medical information in the field of human clinical and molecular data accumulation and analysis for aiding medical diagnostics, prognostics and the evaluation and testing of drug and treatment effectiveness; medical services, namely, cancer care and prevention of cancer, and medical diagnostics, prognostics and evaluation of drug and treatment effectiveness relating to cancer and other diseases; medical counseling; telephone hot line counseling, namely, offering advice regarding cancer prevention, detection, treatment and clinical testing in the field of cancer and other diseases.

Abrégé

Graft-versus-host disease (GVHD) prophylaxis often consists of calcineurin inhibitor-based combinations that indiscriminately curtail T cell receptor signal transduction. This broad inactivation consequently impairs the function of alloreactive pathogenic T cells as well as beneficial regulatory T cells (Treg) and anti-tumor cytotoxic T lymphocytes (CTL). Due to this non-selective approach, GVHD prevention is incomplete and the graft-versus-leukemia (GVL) effect is jeopardized. Disclosed are isolated binding molecules that disrupt the interaction of DLL4 and Notchl and methods of their use, including, but not limited to the treatment of graft versus host disease.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Disclosed are compositions comprising delta-tocotrienol and methods for using the same in the prevention of cancer progression. The methods comprise of reducing, inhibiting, decreasing, and/or preventing the progression of a neoplasm to a cancer (including, but not limited to lung cancer, ovarian cancer, breast cancer, rectal cancer, pancreatic, colon cancer, or intraductal papillary mucinous neoplasm (IPMN) to pancreatic ductal adenocarcinoma) in a subject comprising administering to a subject a therapeutically effective amount of a composition comprising delta-tocotrienol (d-T3).

Classes IPC  ?

• A61K 31/355 - Tocophérols, p. ex. vitamine E
• A61K 31/616 - Acide salicyliqueSes dérivés ayant le groupe hydroxyle en position 2 estérifié, p. ex. acide salicylsulfurique par des acides carboxyliques, p. ex. acide acétylsalicylique
• A61P 35/00 - Agents anticancéreux

Abrégé

This disclosure describes processes for the asymmetric synthesis of trifunctionalized sulfur(VI) containing organic compounds of Formula I and Formula VI, as well as compounds of Formula I and Formula VI prepared by the processes described.

Classes IPC  ?

• C07C 311/15 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons
• C07C 381/10 - Composés contenant des atomes de soufre liés par des liaisons doubles à des atomes d'azote
• C07C 311/16 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à des atomes d'hydrogène ou à un atome de carbone acyclique
• C07C 311/19 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à des atomes d'hydrogène ou à un atome de carbone acyclique à un atome de carbone acyclique d'un radical hydrocarboné substitué par des groupes carboxyle
• C07D 277/36 - Atomes de soufre

Abrégé

This invention relates to a transdiscal screw capable of following a non-linear trajectory. The screw assembly includes a first screw and second screw coupled at a poly-axial joint. The first screw and the second screw capable of rotating independently of each other. The screw can also include a third screw coupled to the second screw at a poly-axial joint such that the first screw, second screw and third screw can rotate independently of each other.

Classes IPC  ?

• A61B 17/86 - Chevilles ou vis
• A61B 17/70 - Dispositifs de mise en position ou de stabilisation de la colonne vertébrale, p. ex. stabilisateurs comprenant un liquide de remplissage dans un implant

Abrégé

Disclosed are compositions and methods for gene transfer in immune effector cells, e.g. to create chimeric antigen receptors (CARs). In particular, polypeptides are disclosed that comprising an antigen-binding region and a heparin binding domain, wherein the antigen-binding region is capable of specifically binding to an immune cell antigen located on an immune effector cell, and wherein the heparin binding domain is capable of binding a viral vector.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

Classes IPC  ?

• C07K 5/117 - Tétrapeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
• A61K 38/34 - Hormone mélanotrope [MSH], p. ex. alpha- ou bêta-mélanotropine
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 49/00 - Préparations pour examen in vivo
• A61K 49/10 - Composés organiques
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 14/68 - Hormone mélanotrope [MSH]
• C07K 14/72 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des hormones

Abrégé

Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a co-stimulatory signaling region having a mutated form of a cytoplasmic domain of CD28 for increased IL-2 production. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes

Produits et services

Downloadable cookbooks Printed cookbooks

Produits et services

Downloadable cookbooks Printed cookbooks

Abrégé

Disclosed herein are dimeric or pentameric antigen binding molecules and methods for making said dimeric or pentameric antigen binding molecules, wherein the isotype of the immunoglobulin monomers is IgA, 1gG4, or IgM. Also disclosed herein are methods of using dimeric antigen binding molecules to treat cancer associated with expression of an oncogene, gene overexpression, or a gene fusion.

Classes IPC  ?

• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux

Abrégé

The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

A method and system for performing bone fusion and/or securing one or more bones, such as adjacent vertebra, are disclosed.

Classes IPC  ?

• A61F 2/44 - Articulations pour l'épine dorsale, p. ex. vertèbres, disques intervertébraux
• A61F 2/30 - Articulations

Abrégé

Peptides useful as inflammasome inhibitors are disclosed and can comprise an H2 helix of a pyrin domain, wherein at least two non-consecutive amino acids of the H2 helix are covalently linked. Methods of treating a subject with a disease comprising administering to the subject the disclosed peptides are also disclosed. Further, disclosed herein are methods of inhibiting binding between a first polypeptide comprising a pyrin domain and a second polypeptide comprising a pyrin domain, the method comprising contacting either the first polypeptide or the second polypeptide with the disclosed peptides.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 38/00 - Préparations médicinales contenant des peptides

Produits et services

Implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations for humans for the treatment of cancer; Pharmaceutical products for humans for the treatment of cancer; Therapeutic pharmaceutical for humans for the treatment of cancer; Pharmaceutical preparations for humans for the treatment of cancer

Produits et services

Implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer; Pharmaceutical preparations for the treatment of cancer

Produits et services

Providing an on-line forum for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care

Produits et services

Providing an on-line forum for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care

Produits et services

Recorded computer software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing on-line non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing a website featuring non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing online non-downloadable computer software platforms for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care

Produits et services

Recorded computer software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing on-line non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing a website featuring non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing online non-downloadable computer software platforms for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care

Produits et services

Recorded computer software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care. Providing an on-line forum for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care. Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing on-line non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing a website featuring non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing online non-downloadable computer software platforms for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care.

Abrégé

The present disclosure relates to systems and methods for the assessment of early adverse events (AE) to predict and improve a clinical outcome of a treatment regimen.

Classes IPC  ?

• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
• G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
• G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients

Abrégé

Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage T-cells to destroy TAG-72-expressing malignant cells.

Classes IPC  ?

• C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/46 - Immunoglobulines hybrides

Abrégé

Disclosed herein is a system that addresses all of the current challenges described above by combining three existing technologies and an improved nuclear RNA delivery system to generate a first-in-class cellular therapy that can secrete a cancer specific suicide gene for the treatment of several cancers. Also disclosed herein is a 'Trojan-Horse' like genetic construct aimed at engineering a chemo-sensitive dominant clone for adaptive therapy in cancers, such as leukemia. In some embodiments, cells, such as cancer cells from a subject, are engineered with suicide genes to promote a bystander effect in neighboring cancer cells once returned to the subject. In some embodiments, these cells are further engineered to be clonally dominant, e.g. by deleting or mutating tumor suppressor genes in the cells, overexpressing oncogenes, or any combination thereof. Once the engineered cells have reached a target clonal dominance, the suicide gene can be induced, thereby promoting the bystander effect.

Classes IPC  ?

• C12N 5/0781 - Cellules BLeurs progéniteurs
• C12N 15/86 - Vecteurs viraux
• A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• C07K 14/155 - Lentiviridae, p. ex. virus du déficit immunitaire humain [HIV], virus visna-maedi ou virus de l'anémie infectieuse équine
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 5/10 - Tétrapeptides

Abrégé

Disclosed herein is an mRNA vaccine encoding a variant (double mutant form) of the survivin polypeptide and methods for treating a malignancy, such as myeloma, or for inducing an immune response, by administering the variant survivin mRNA vaccine. Also disclosed are methods for treating a malignancy using the disclosed mRNA vaccine.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61K 31/195 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino

Abrégé

The recent development of immunotherapies has ushered in a new era of cancer treatment. These therapeutics have led to revolutionary breakthroughs; however, the efficacy has been modest and is often restricted to a subset of patients. Hence, identification of which cancer patients will benefit from immunotherapy is essential. Multiplex immunofluorescence (mIF) microscopy allows for the assessment and visualization of the tumor immune microenvironment (TIME).

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

Disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced expression of a 12 Chemokine gene signature; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLAmatched TILs.

Classes IPC  ?

• A61K 31/70 - Hydrates de carboneSucresLeurs dérivés
• A61P 35/00 - Agents anticancéreux
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The disclosure provides a method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof. The method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Classes IPC  ?

• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 207/12 - Atomes d'oxygène ou de soufre

Abrégé

Disclosed are inhibitors for CDK12/13 and uses thereof. Methods of using the disclosed compounds to treat cancer are also disclosed.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol

Abrégé

The present disclosure provides compounds which find use as ULK1 inhibitors and their use in the treatment of medical disorders, in particular disorders associated with abnormal cellular proliferation such as cancers.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou

Produits et services

Conducting of business conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Conducting of educational conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Arranging and conducting of conferences in the field of healthcare, medical research, cancer care, life sciences, and education